John Sourbeer
Stock Analyst at UBS
(0.56)
# 4,155
Out of 5,182 analysts
44
Total ratings
33.33%
Success rate
-20.44%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $8.77 | +42.53% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $127.38 | -5.79% | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $254.80 | +39.32% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $46 → $48 | $41.03 | +16.06% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $114.19 | +110.18% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $13.73 | +71.16% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $17.25 | +160.87% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.34 | +49.25% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $498.34 | -3.68% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $36.76 | +177.48% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $22.33 | +123.91% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $102.87 | +24.43% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $8.77
Upside: +42.53%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $127.38
Upside: -5.79%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $254.80
Upside: +39.32%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $46 → $48
Current: $41.03
Upside: +16.06%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $114.19
Upside: +110.18%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $13.73
Upside: +71.16%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $17.25
Upside: +160.87%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.34
Upside: +49.25%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $498.34
Upside: -3.68%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $36.76
Upside: +177.48%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $22.33
Upside: +123.91%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $102.87
Upside: +24.43%